|
Neuroendocrine Tumors
|
0.100 |
Biomarker
|
group |
BEFREE |
Lutetium, in combination with somatostatin analogs, has proven efficacy to treat gastroenteropancreatic neuroendocrine tumors in candidates with somatostatin receptor-positive advanced tumors and normal renal function.
|
30972265 |
2019 |
|
Neuroendocrine Tumors
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Imaging of somatostatin receptor expression is an established technique for staging of neuroendocrine neoplasia and determining the suitability of patients for peptide receptor radionuclide therapy.
|
30442752 |
2019 |
|
Neuroendocrine Tumors
|
0.100 |
Biomarker
|
group |
BEFREE |
The PPoma is classified as a neuroendocrine tumor (NET) not functioning that overexpresses SSTR 2 (somatostatin receptor subtype 2).
|
31385111 |
2019 |
|
Neuroendocrine Tumors
|
0.100 |
Biomarker
|
group |
BEFREE |
The aim of the present prospective study was to estimate the potential impact of single-photon emission computed tomography somatostatin receptor scintigraphy using 99mTc-Tektrotyd on diagnosis, treatment response, and prognosis in patients with neuroendocrine tumors of the lungs.
|
31079574 |
2019 |
|
Neuroendocrine Tumors
|
0.100 |
Biomarker
|
group |
BEFREE |
The results were the following: Among the 139 subjects included, the majority had a midgut NET (54.2%), 81.3% had CS, and 93% received somatostatin analogues.
|
30909590 |
2019 |
|
Neuroendocrine Tumors
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Somatostatin receptors are commonly expressed in different neuroendocrine tumors, but whether this also holds for parathyroid tumors remains unknown.
|
31336364 |
2019 |
|
Neuroendocrine Tumors
|
0.100 |
Biomarker
|
group |
BEFREE |
Detection rate of unknown primary tumour by using somatostatin receptor PET/CT in patients with metastatic neuroendocrine tumours: a meta-analysis.
|
31004334 |
2019 |
|
Neuroendocrine Tumors
|
0.100 |
Biomarker
|
group |
BEFREE |
Ga-DOTATATE is a radiolabeled somatostatin analog used for the detection and characterization of somatostatin receptor (SSR)-overexpressing tumors, particularly well-differentiated neuroendocrine tumors.
|
30688738 |
2019 |
|
Neuroendocrine Tumors
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist <sup>177</sup>Lu-Satoreotide Tetraxetan.
|
31439583 |
2019 |
|
Neuroendocrine Tumors
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Neuroendocrine tumors (NETs) express somatostatin receptors, which can be targeted with radiolabeled peptides.
|
30267071 |
2019 |
|
Neuroendocrine Tumors
|
0.100 |
Biomarker
|
group |
BEFREE |
177Lu‑DOTATATE was recently approved for the treatment of somatostatin receptor (SSTR)‑positive neuroendocrine tumors (NETs).
|
31638190 |
2019 |
|
Neuroendocrine Tumors
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Pheochromocytomas (PHEOs) and paragangliomas (PGLs) are neuroendocrine tumors that express somatostatin receptors (SSTRs), a phenomenon that constitutes a basis for tumor imaging and treatment with somatostatin analogues and peptide receptor radionuclide therapy.
|
30529752 |
2019 |
|
Neuroendocrine Tumors
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Somatostatin receptors are highly expressed in neuroendocrine tumors, and many radiolabeled somatostatin analogs for diagnosis and treatment have been developed.
|
30604401 |
2019 |
|
Neuroendocrine Tumors
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The results of this study confirm an increased rate of gallstones development and related complications in patients with neuroendocrine tumors (NETs) treated with somatostatin analogs (SSAs).
|
31694893 |
2019 |
|
Neuroendocrine Tumors
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Prognostic Value of Maximum Standardized Uptake Value in 68Ga-Somatostatin Receptor Positron Emission Tomography for Neuroendocrine Tumors: A Systematic Review and Meta-analysis.
|
31283601 |
2019 |
|
Neuroendocrine Tumors
|
0.100 |
Biomarker
|
group |
BEFREE |
More recently, PET imaging with <sup>68</sup>Ga-labeled somatostatin receptor (SSR) analogs allows neuroendocrine tumors to be imaged with much higher sensitivity.
|
31468190 |
2019 |
|
Neuroendocrine Tumors
|
0.100 |
Biomarker
|
group |
BEFREE |
Neuroendocrine tumors (NET) are rare tumors for which somatostatin analogs (SSA) are used not only for symptom control due to a functioning tumor, but also for the disease control of unresectable NET.
|
30267338 |
2019 |
|
Neuroendocrine Tumors
|
0.100 |
Biomarker
|
group |
BEFREE |
Prognostic value of somatostatin receptor expressing tumor volume calculated from <sup>68</sup>Ga-DOTATATE PET/CT in patients with well-differentiated neuroendocrine tumors.
|
31350603 |
2019 |
|
Neuroendocrine Tumors
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In the presence of prior malignancy, it should be kept in mind that malignancies apart from neuroendocrine tumors express somatostatin receptors, and they can show Ga-DOTATATE uptake.
|
31306201 |
2019 |
|
Neuroendocrine Tumors
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Ga-DOTANOC PET/CT confirmed somatostatin receptor (SR) expression in hypervascularized liver lesions suggestive of neuroendocrine tumor that was later diagnosed as hepatocellular carcinoma (HCC).
|
30672751 |
2019 |
|
Neuroendocrine Tumors
|
0.100 |
AlteredExpression
|
group |
BEFREE |
This case illustrates that cerebral metastases in neuroendocrine tumors may occur many years after initial diagnosis, and their somatostatin receptor expression may rise within a few months to a level that reasonably justifies further peptide receptor radiotherapy.
|
30371585 |
2019 |
|
Neuroendocrine Tumors
|
0.100 |
Biomarker
|
group |
BEFREE |
Somatostatin analogs (SSAs) are standard for symptomatic patients with neuroendocrine tumors (NETs).
|
30171068 |
2019 |
|
Neuroendocrine Tumors
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Assessment of treating metastatic ileal neuroendocrine tumors (NETs) with complete resection of primary tumor, nodal and liver metastases, plus administration of long-acting somatostatin analogues (SSAs).
|
31346887 |
2019 |
|
Neuroendocrine Tumors
|
0.100 |
AlteredExpression
|
group |
BEFREE |
177Lu-octreotate is an FDA-approved radionuclide therapy for patients with gastroenteropancreatic neuroendocrine tumours (NETs) expressing somatostatin receptors.
|
30730850 |
2019 |
|
Neuroendocrine Tumors
|
0.100 |
Biomarker
|
group |
BEFREE |
Higher affinity of Ga compounds to somatostatin receptors (SSTRs) and PET better image resolution increased interest in Ga-labelled somatostatin analogs in the management of neuroendocrine tumours (NETs).
|
31343614 |
2019 |